Association Between Immune-Related AEs and Clinical Outcome Following Nivolumab Treatment for mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Association Between Immune-Related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
In Vivo 2020 Sep 01;34(5)2647-2652, K Kobayashi, Y Iikura, M Hiraide, T Yokokawa, T Aoyama, S Shikibu, K Hashimoto, K Suzuki, H Sato, E Sugiyama, M Tajima, T HamaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.